ABB  Vol.3 No.6 A , October 2012
NS-398 induces caspase-dependent, mitochondria-mediated intrinsic apoptosis of hepatoma cells
Abstract: The present study was conducted to investigate whether mitochondrial pathway of apoptosis is involved in cyclooxygenase-2 (COX-2) inhibitor-induced growth inhibition of hepatoma cells. The growth rate and pattern of NS-398 (selective COX-2 inhibitor)-treated Hep3B hepatoma cells were analyzed by microscopic examination, DNA fragmentation gel analysis and flow cytometry followed by the cleavage of down-stream caspase 3 and the release of cytosolic fraction of cytochrome c assessed by Western blot analysis. NS-398 induced the growth inhibition of hepatoma cells depending on the concentration of this COX-2 inhibitor and time sequence. Ladder patterned-DNA fragmentation and cytometric redistribution to sub-G1 phase in cell cycle were revealed in NS-398-induced growth inhibition of hepatoma cells. Cytochrome c was translocated from mitochondria to cytosol in time-dependent manner following NS-398 treatment to hepatoma cells. COX-2 inhibitor induces the growth inhibition of hepatoma cells via caspase-dependent, mitochondria-mediated intrinsic apoptosis pathway. These results strongly suggest the possibility of therapeutic implication of COX-2 inhibitor in HCC.
Cite this paper: Song, I. , Kim, S. , Shin, H. , Kang, H. and Kim, E. (2012) NS-398 induces caspase-dependent, mitochondria-mediated intrinsic apoptosis of hepatoma cells. Advances in Bioscience and Biotechnology, 3, 649-656. doi: 10.4236/abb.2012.326084.

[1]   El-Serag, H.B. and Rudolph, K.L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.

[2]   Sherman, M. (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Seminar in Liver Disease, 25, 143-154.

[3]   Song, I.H. and Kim, K.S. (2009) Current status of liver diseases in Korea: hepatocellular carcinoma. Korean Journal of Hepatology, 15(Suppl 6), S50-S59.

[4]   Lopez, P.M., Villanueva, A. and Llovet, J.M. (2006) Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Alimentary Pharmacology and Therapeutics, 23, 1535-1547.

[5]   Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D. and Bruix, J.; SHARP Investigators Study Group. (2008) Sorafenib in advanced hepatocellular carcinoma. New England Journal Medicine, 359, 378-390.

[6]   Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., Luo, R., Feng, J., Ye, S., Yang, T.S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W.Y., Pan, H., Burock, K., Zou, J., Voliotis, D. and Guan, Z. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, place-bo-controlled trial. Lancet Oncology, 10, 25-34.

[7]   Koga, H. (2003) Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer, 98, 661-667.

[8]   Chang, W.S., Yang, M.D., Tsai, C.W., Cheng, L.H., Jeng, L.B., Lo, W.C., Lin, C.H., Huang C.Y. and Bau, D.T. (2012) Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chinese Journal of Physiology, 55, 1-7.

[9]   Ogunwobi, O.O., Wang, T., Zhang, L. and Liu, C. (2012) Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 27, 566-578.

[10]   Nzeako, U.C., Guicciardi, M.E., Yoon, J.H., Bronk, S.F. and Gores, G.J. (2002) COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology, 35, 552-559.

[11]   Abiru, S., Nakao, K., Ichikawa, T., Migita, K., Shigeno, M., Sakamoto, M., Ishikawa, H., Hamasaki, K., Nakata, K. and Eguchi, K. (2002) Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology, 35, 1117-1124.

[12]   Kern, M.A., Schoneweiss, M.M., Sahi, D., Bahlo, M., Haugg, A.M., Kasper, H.U., Dienes, H.P., Koferstein, H., Breuhahn, K. and Schirmacher, P. (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 25, 1193-1199.

[13]   Fodera, D., D'Alessandro, N., Cusimano, A., Poma, P., Notarbartolo, M., Lampiasi, N., Montalto, G. and Cervello, M. (2004) Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Annals of the New York Academy of Sciences, 1028, 440-449.

[14]   Li, S., Tong, Q., Zhang, W., Wang, Q., Chen, Z. and Wu, Q. (2008) Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Investigation, 26, 333-337.

[15]   Nakamoto, N., Higuchi, H., Kanamori, H., Kurita, S., Tada, S., Takaishi, H., Toda, K., Yamada, T., Kumagai, N., Saito, H. and Hibi, T. (2006) Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo. International Journal of Oncology, 29, 625-635.

[16]   Xie, H., Gao, L., Chai, N., Song, J., Wang, J., Song, Z., Chen, C., Pan, Y., Zhao, L., Sun, S., Wu, K., Feitelson, M.A., Liu, J. and Fan, D. (2009) Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Molecular Carcinogenesis, 48, 56-65.

[17]   Yamanaka, Y., Shiraki, K., Inoue, T., Miyashita, K., Fuke, H., Yamaguchi, Y., Yamamoto, N., Ito, K., Sugimoto, K. and Nakano, T. (2006) COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. International Journal of Molecular Medicine, 18, 41-47.

[18]   Kern, M.A., Haugg, A.M., Koch, A.F., Schilling, T., Breuhahn, K., Walczak, H., Fleischer, B., Trautwein, C., Michalski, C., Schulze-Bergkamen, H., Friess, H., Stremmel, W., Krammer, P.H., Schirmacher, P. and Müller, M. (2006) Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Research, 66, 7059-7066.

[19]   Okada, H. and Mak, T.W. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Reviews Cancer, 4, 592-603.

[20]   Budihardjo, I., Oliver, H., Lutter, M., Luo, X. and Wang, X. (1999) Biochemical pathways of caspase activation during apoptosis. Annual Review of Cell and Developmental Biology, 15, 269-290.

[21]   Salvesen, G.S. and Dixit, V.M. (1997) Caspases: intracellular signaling by proteolysis. Cell, 91, 443-446.

[22]   Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: enemies within. Science, 281, 1312-1316.

[23]   Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I. and Green, D.R. (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biology, 2, 156-162.

[24]   Simonetti, R.G., Liberati, A., Angiolini, C. and Pagliaro, L. (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Annals of Oncology, 8, 117-136.

[25]   Lee, N.O., Park, J.W., Lee, J.A., Shim, J.H., Kong, S.Y., Kim, K.T. and Lee, Y.S. (2012) Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2. Journal of Cancer Research and Clinical Oncology, 138, 73-84.

[26]   Leng, J., Han, C., Demetris, A.J., Michalopoulos, G.K. and Wu, T. (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology, 38, 756-768.

[27]   Li, H.X., Chang, X.M., Song, Z.J. and He, S.X. (2003) Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma. World Journal of Gastroenterology, 9, 674-677.

[28]   Ogunwobi, O.O. and Liu, C. (2011) Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathway. Clinical and Experimental Metastasis, 28, 721-731.

[29]   Kern, M.A., Schubert, D., Sahi, D., Schoneweiss, M.M., Moll, I., Haugg, A.M., Dienes, H.P., Breuhahn, K. and Schirmacher, P. (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 36, 885-894.

[30]   Thun, M.J., Namboodiri, M.M. and Heath, C.W. Jr. (1991) Aspirin use and reduced risk of fatal colon cancer. New England Journal of Medicine, 325, 1593-1596.

[31]   Giovannucci, E., Egan, K.M., Hunter, D.J., Stampfer, M.J., Colditz, G.A., Willett, W.C. and Speizer, F.E. (1995) Aspirin and the risk of colorectal cancer in women. New England Journal of Medicine, 333, 609-614.

[32]   Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M. and Attali, P. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101, 635-639.

[33]   van Stolk, R., Stoner, G., Hayton, W.L., Chan, K., DeYoung, B., Kresty, L., Kemmenoe, B.H., Elson, P., Rybicki, L., Church, J., Provencher, K., McLain, D., Hawk, E., Fryer, B., Kelloff, G., Ganapathi, R. and Budd, G.T. (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clinical Cancer Research, 6, 78-89.

[34]   Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L.K. and Levin, B. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New England Journal of Medicine, 342, 1946-1952.

[35]   Tucker, O.N., Dannenberg, A.J., Yang, E.K., Zhang, F., Teng, L., Daly, J.M., Soslow, R.A., Masferrer, J.L., Woerner, B.M., Koki, A.T. and Fahey, T.J. 3rd. (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research, 59, 987-990.

[36]   Zimmermann, K.C., Sarbia, M., Weber, A.A., Borchard, F., Gabbert, H.E. and Schror, K. (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Research, 59, 198-204.

[37]   Qiu, D.K., Ma, X., Peng, Y.S. and Chen, X.Y. (2002) Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World Journal of Gastroenterology, 8, 815-817.

[38]   Cusimano, A., Fodera, D., D'Alessandro, N., Lampiasi, N., Azzolina, A., Montalto, G. and Cervello, M. (2007) Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biology and Therapy, 6, 1461-1468.

[39]   Pyrko, P., Soriano, N., Kardosh, A., Liu, Y.T., Uddin, J., Petasis, N.A., Hofman, F.M., Chen, C.S., Chen, T.C. and Schonthal, A.H. (2006) Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Molecular Cancer, 5, 19.

[40]   Nagahara, T., Okano, J. and Murawaki, Y. (2007) Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncology Reports, 18, 1281-1290.

[41]   Cheng, A.S., Chan, H.L., Leung, W.K., Wong, N., Johonson, P.J. and Sung, J.J. (2003) Specific COX-2 inhibitor. NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. International Journal of Oncology, 23, 113-119.

[42]   Yu, Y., Gong, R., Mu, Y., Chen, Y., Zhu, C., Sun, Z., Chen, M., Liu, Y., Zhu, Y. and Wu, J. (2011) Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. Journal of Immunology, 187, 4844-4860.

[43]   Baek, J.Y., Hur, W., Wang, J.S., Bae, S.H. and Yoon, S.K. (2007) Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World Journal of Gastroenterology, 13, 1175-1181.

[44]   Huang, D.S., Shen, K.Z., Wei, J.F., Liang, T.B., Zheng, S.S. and Xie, H.Y. (2005) Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. World Journal of Gastroenterology, 11, 204-207.